Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lessons from a National Liquid Biopsy Program to Provide Cancer Testing and Treatment for Patients with Advanced Solid Tumors.

Current oncology (Toronto, Ont.) - 29 Dec 2025

Lapuk Anna, Furman Benjamin L S, Feijao Pedro, Baran Ebru, Brahmbhatt Sonal, Chan Betty, Nip Ka Mun, Kense Adrian, Murphy Brenda, Miller Ruth, Funari Vincent, Parker Alicja, McConechy Melissa K, Kassam Shaqil, Awan Arif A, Lo Bryan, Breadner Daniel, Stein Barry D, Huntsman David G

Abstract excerpt

Personalized cancer treatment depends on the accurate and timely detection of the patient tumor variants. LBx enables minimally invasive tumor mutation profiling. We report results of a pan-Canadian LBx program for patients with advanced solid tumors. Plasma samples were tested at Imagia Canexia Health accredited laboratory using the clinically validated Follow It 38-gene panel. A proprietary platform was used to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Canada
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liquid Biopsy

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41590338
DOI: 10.3390/curroncol33010018
PMCID: PMC12840088

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lessons from a National Liquid Biopsy Program to Provide Cancer Testing and Treatment for Patients with Advanced Solid Tumors.PMID 41590338Read ↗

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancerSemantic proximity Read ↗

Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University).Semantic proximity Read ↗

Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) PatientsSemantic proximity Read ↗

Implementation of circulating tumour DNA multi-target mutation testing in plasma: a perspective from an external quality assessment providers' survey.Semantic proximity Read ↗

The significance of using liquid biopsy to improve treatment outcomes for metastatic patientsSemantic proximity Read ↗

Assessing In House Comprehensive Genomic Profiling by Liquid Biopsy for NSCLC PatientsSemantic proximity Read ↗

A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers.Semantic proximity Read ↗

Unlocking precision oncology by establishing a nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer: the BALLETT studySemantic proximity Read ↗

The implementation of liquid biopsies in routine care of patients with advanced solid cancer (LIQPLAT): a study protocol for a single arm trialSemantic proximity Read ↗

Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time.Semantic proximity Read ↗

Multi-Analyte Liquid Biopsies for Treatment Guidance in Advanced Refractory Cancers: Findings of the LIQUID IMPACT TrialSemantic proximity Read ↗

A Canadian Guideline on the Use of Next-Generation Sequencing in OncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.